Indole-pyrimidine hybrids with anticancer therapeutic potential

Zhang Bin1,2,3, Zhao Bing1, Li Xinchun1

  • 1Affiliated Zhumadian Central Hospital, Huanghuai University, Zhumadian, China.

PubMed

Insights

Indole-pyrimidine hybrids show promise as anticancer agents by targeting multiple cancer hallmarks. This review summarizes recent advances in these compounds, focusing on structure-activity relationships and mechanisms of action for drug development.

Area of Science:

  • Medicinal Chemistry
  • Drug Discovery
  • Oncology

Background:

  • Indole derivatives are versatile anticancer agents targeting cancer hallmarks like proliferation and apoptosis.
  • Pyrimidine derivatives act as molecular mimics or enzyme inhibitors, exploiting cancer-specific vulnerabilities.
  • Hybridizing indole and pyrimidine scaffolds offers a promising strategy for novel anticancer therapeutics.

Purpose of the Study:

  • To review the current landscape of indole-pyrimidine hybrids with anticancer potential.
  • To summarize structure-activity relationships and mechanisms of action for these hybrids.
  • To guide the rational design of new anticancer drug candidates.

Main Methods:

  • Literature search for indole-pyrimidine hybrids with anticancer activity published from 2021 to date.
  • Analysis of structure-activity relationships (SAR) of identified compounds.
  • Discussion of mechanisms of action for promising drug candidates.

Main Results:

  • Identified a growing body of research on indole-pyrimidine hybrids demonstrating significant anticancer potential.
  • Detailed SAR studies reveal key structural features contributing to efficacy.
  • Mechanisms of action involve targeting multiple cancer pathways.

Conclusions:

  • Indole-pyrimidine hybrids represent a potent class of anticancer agents with diverse mechanisms.
  • Further research into SAR and mechanisms will facilitate the development of novel therapeutics.
  • This hybrid scaffold holds significant promise for future cancer drug discovery.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
801
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
594